Prof Geoff Isbister
Prof Geoff Isbister is a clinician researcher at the University of Newcastle, a NHMRC Senior Research Fellow and Consultant Toxicologist to the National Poison Centre Network. He conducts research in clinical toxicology and toxinology, investigating the pathophysiology of poisoned and envenomed patients, as well as the effectiveness and safety of antidotes such as antivenom. He has been key in establishing a collaborative research program in Australia in clinical toxicology, which undertakes multicentre clinical studies backed by state of the art laboratory research. His research challenges long held views about treatment of poisoned and envenomed patients, making clinicians re-look at what evidence there is for various treatments. Over the last 15 years he has established the Australian Snakebite Project – ASP – which has changed the treatment of snakebite in Australia.
Keynote speaker sponsored by:
Prof Jennifer Martin
Prof Jennifer Martin AC FAA is the Director of the Griffith Institute for Drug Discovery at Griffith University and a recent ARC Laureate Fellow at the Institute for Molecular Bioscience, University of Queensland. Prof Martin was recognised in the 2018 Australia Day Honours List with the highest civilian honour Companion of the Order of Australia for “eminent service to science, and to scientific research, particularly in the field of biochemistry and protein crystallography applied to drug-resistant bacteria, as a role model, and as an advocate for gender equality in science“.
Prof Jennifer Martin
Professor Jennifer Martin is a leading clinical pharmacologist. She is the Chair of the discipline of Clinical Pharmacology in the School of Medicine and Public Health at the University of Newcastle and a senior staff specialist in internal medicine at the John Hunter Hospital.
Professor Martin is also Director of the NHMRC-funded Australia Centre for Cannabinoid Clinical and Research Excellence (ACRE), Australia’s first federally-funded research centre in medicinal cannabinoids to ensure quality and safety in the implementation of medicinal cannabis use in the community.
She is also lead chief investigator on a $1.96 million Cancer Council NSW pathways grant to develop a personalised chemotherapy dosing system for cancer patients, and more than $3m in funding for medicinal cannabis research as part of NSW Health’s Clinical Cannabis Medicines Program. In addition, Professor Martin is part of Australia’s first medical cannabis trial to produce world-class pharmacokinetic analysis and sophisticated modelling to inform drug dosage and frequency of administration. Based at the Hunter Medical Research Institute, the former Rhodes Scholar leads a team of pharmacy and medicine experts together with pharmacoepidemiologists and pharmacoeconomists.